- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.
Trial Phase
Trial Status
Paid Participation
Trial Details
Key Eligibility Criteria
30 Participants Needed
Trial Details
Key Eligibility Criteria
500 Participants Needed
Trial Details
Key Eligibility Criteria
30 Participants Needed
Trial Details
Key Eligibility Criteria
75 Participants Needed
Trial Details
Key Eligibility Criteria
60 Participants Needed
"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."
"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."
"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."
"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."
"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."
Know someone looking for new options?
Spread the word
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Amyotrophic Lateral Sclerosis trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Amyotrophic Lateral Sclerosis is 12 months.
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
Most recently, we added Speech Perception for ALS, Acamprosate for ALS and Cromolyn Sodium for ALS to the Power online platform.
There is still no one-shot “cure” for ALS, but several newer drugs—riluzole, edaravone, AMX0035, and the gene-specific therapy tofersen—can modestly slow the disease, and dozens of gene, antisense, immune-modulating and stem-cell treatments are now in late-stage clinical trials. Specialists therefore view ALS care as a rapidly evolving field: staying connected to an ALS center, asking about genetic testing, and monitoring clinical-trial options offer the best chance to benefit from these emerging therapies while comprehensive supportive care maximizes quality of life today.
Most people with ALS live 2–5 years, but about 5–10 % are alive at 10 years and fewer than 1 % reach 20 years—usually those who are younger, have a slow limb-onset form, and/or use long-term ventilatory support. The longest well-documented survivor was physicist Stephen Hawking, who lived roughly 55 years after symptom onset, showing that while such extreme longevity is possible, it is an extraordinary outlier rather than the norm.
ALS usually doesn’t damage the automatic nerves that create an erection, so many men can still “get hard.” If weakness, fatigue, mood issues or medicines make erections unreliable, standard treatments like Viagra-type pills, vacuum pumps, position changes or counselling often help—so bring any problems up with your neurologist or a urologist early.
Doctors don’t follow one standard “7-stage” chart for ALS; most use the King’s system (one body region affected → two → three → need for a feeding tube → need for breathing support → death) or the Milano-Torino (MiToS) system, which grades loss of independence in 1, 2, 3, or 4 key functions before death. The public 7-step list you may see online (symptom onset, diagnosis, independent phase, assisted independence, moderate loss, advanced loss, end-of-life) is simply a lay summary of these milestones. Ask your neurologist which staging scale they use so you can match care plans, equipment, and treatments to your current stage.
There isn’t one universally “best” hospital for ALS; the goal is to be seen at an ALS Association-Certified Treatment Center of Excellence or similar multidisciplinary clinic, where neurologists, respiratory, rehab, nutrition and social-work specialists collaborate—an approach shown to prolong survival. Use the ALS Association (als.org/clinics) or MDA clinic finder to locate the nearest accredited program, then weigh travel distance, insurance coverage and access to clinical trials; highly regarded examples include Mass General’s Healey Center (MA), Johns Hopkins (MD), Mayo Clinic (MN/FL), Northwestern’s Les Turner Center (IL), Cedars-Sinai and UCSF (CA).
There is no officially adopted “new” name—amyotrophic lateral sclerosis (ALS) is still the formal medical term used in disease classifications worldwide. People may hear it called “motor neurone/neuron disease (MND)” in the UK and other countries or “Lou Gehrig’s disease” in North America, but these are regional synonyms rather than a recent name change.
ALS research is a worldwide team effort: leading university clinics (e.g., Johns Hopkins, Mass General/Harvard, Mayo Clinic, University of Sheffield), large research networks such as NEALS, Project MinE, Answer ALS and Target ALS, government funders (NIH, CDC, European JPND), patient-driven nonprofits (ALS Association, ALS TDI) and biotech/pharma companies like Biogen, Amylyx and BrainStorm all run studies. To see exactly who is doing what and how to join in, visit the NEALS Trial Finder or ClinicalTrials.gov, or enroll in the CDC National ALS Registry, which sends research invitations to registered patients.
Gentle, short-distance walking can help people with ALS keep their joints moving, maintain endurance, and feel better emotionally, but it will not stop the disease itself. The key is to walk at a pace that does not leave you wiped out after 30 minutes, use braces or a helper to prevent falls, and adjust or switch to seated or pool exercises as weakness advances under the guidance of your neurologist or physical therapist.
Today there is no way to “recover” from ALS because once the motor nerves die they cannot be rebuilt; the goal of treatment is to slow the disease and manage symptoms. Medicines such as riluzole, edaravone, the new combination pill AMX0035, and the gene-targeted drug tofersen (for certain inherited cases) plus coordinated breathing, nutrition and physical therapy can extend survival and preserve independence for months to years, while dozens of clinical trials continue to search for a true cure.
Current research shows that IVIg does not meaningfully slow down or improve ALS; at best, a few small studies saw short-lived effects that disappeared within weeks and could not be reproduced. Because of this, expert guidelines advise against using IVIg for ALS outside of clinical trials—discuss other FDA-approved options (riluzole, edaravone) and participation in research studies with your neurologist instead.